ClinicalTrials.gg
Active, not recruitingNCT06922110X-NOVA-OLEUpdated Oct 13, 2026

An Open-Label Study of Azetukalner in Major Depressive Disorder

A Phase 3 interventional study of Azetukalner in Major Depressive Disorder, sponsored by Xenon Pharmaceuticals Inc.. Active, not recruiting at 71 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Xenon Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment

Updated Oct 13, 2026Now Active, not recruiting1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
460
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.

Planned enrollment
164th of 1,323
460 · median 70
Started
2025
with 69 others
Phase 3
240 of 1,500
21 open now
Primary completion
2027-01
later than 64 of 258 live
Registered
1,387th of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 164th largest by planned enrollment of the 1,323 interventional ones that give a count, is one of 70 that started in 2025, is one of 240 in phase 3, reaches primary completion later than 64 of the 258 other live ones, and was the 1,387th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

210 more — sign in →

All 215 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

X-NOVA-OLE is a multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner as a monotherapy in adult participants who successfully completed an antecedent Phase 3 study of azetukalner in Major Depressive Disorder (MDD).

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Depression
  • Antidepressant
  • XEN1101
  • Azetukalner
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant successfully completed the treatment period of an antecedent azetukalner Phase 3 study in MDD.
  • Participant provides written to participate in the study, is able to understand the procedures and study requirements, and agrees to abide by them.
  • Participant is willing to comply with the requirements.
  • Male participants must agree not to donate sperm until 3 months after the last dose of study drug. Female participants must agree not to donate ova until 3 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Participant met any of the withdrawal criteria, or discontinued study drug early, or was terminated early from an antecedent study.
  • Participant had any protocol deviations in an antecedent azetukalner study that, in the opinion of the investigator, would preclude participation in this study.
  • Participant is unable to comply with study procedures or is inappropriate for the study, as judged by the investigator.
  • Participant has any medical condition, personal circumstance, or ongoing AE (from an antecedent study) that, in the opinion of the investigator, exposes the participant to unacceptable risk by participating in the study or prevents adherence to the protocol.
  • Female participant who is pregnant, breastfeeding, or planning to become pregnant within 3 months after the last dose of study drug.
  • Participant is planning to enter a clinical study with a different drug or planning to use any experimental device for treatment of any medical condition during the study or within 28 days after completion of this study.
  • Participant is judged to have a significant risk for self-harm or suicidal behavior or is considered to be an imminent danger to themself or others, as determined by the C-SSRS or in the opinion of the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
460 participants (estimated)

Study arms

  • Experimental
    Azetukalner 20 mg

    Drug: Azetukalner

Interventions

  • Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 52 weeks.

06

What researchers measure

Primary outcomes

  1. Severity and frequency of treatment-emergent adverse events, serious adverse events, adverse events of special interest, and events of clinical interest

    Time frame: From the start of treatment in the open-label extension study through 8 weeks after the last dose

Secondary outcomes

  1. Change from baseline in the Hamilton Depression Rating Scale, 17-Item (HAMD-17) total score over time

    Time frame: From baseline through the active extension treatment (Week 52)

  2. Change from baseline in the Snaith-Hamilton Pleasure Scale (SHAPS) total score over time

    Time frame: From baseline through the active extension treatment (Week 52)

  3. Change in the Clinical Global Impression of Severity (CGI-S) score over time

    Time frame: From baseline through the active extension treatment (Week 52)

  4. Change from baseline in Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) total score, Q-LES-Q-SF medication and life satisfaction and contentment in item scores over time

    Time frame: From baseline through the active extension treatment (Week 52)

  5. Change from baseline in Sheehan Disability Scale (SDS) total score and subscale scores over time

    Time frame: From baseline through the active extension treatment (Week 52)

07

Study locations

71 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jan 2027, 22 months after the start.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's planned 22 months is below that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2025
First posted
Apr 10, 2025
StartActual
Mar 18, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Mar 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Active, not recruiting
changed Oct 13, 2026
Sites
1 site added, 1 site removed
Show site
  • Irvine Clinical Research · Irvine, United States
Show 1 removed
  • Irvine Clinical Research · Irvington District, United States
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Enrolling by invitation→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • Irvine Clinical Research · Irvine, United States
    Show 1 removed
    • Irvine Clinical Research · Irvington District, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06922110
Responsible party
Sponsor
First posted
Apr 10, 2025
Start date
Mar 18, 2025
Primary completion
Jan 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: XEN1101

Start the discussion